ArticleFrontiers in endocrinology2021
Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center.
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Validity of galactin-3 in acromegaly: comparison with traditional markers.Irish journal of medical science · 2024Trial
- Acromegaly and cardiovascular disease: mechanisms, clinical impact, and evolving management.Endocrine reviews · 2026Review
- [Efficacy of octreotide LAR and lanreotide autogel in acromegaly assessed by SAGIT].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- The Journey of Acromegaly Towards Treatment: A Single-Center Study.Journal of personalized medicine · 2026Article
- Evaluation of temporal muscle thickness in subjects with acromegaly: a follow-up study.Therapeutic advances in endocrinology and metabolism · 2026Article
- Cardiomyopathy in women with acromegaly: clinical characteristics and associated factors in a Colombian multicenter registry.Frontiers in endocrinology · 2026Article
- Adherence, duration and healthcare costs in a real-world population of patients with acromegaly.Journal of comparative effectiveness research · 2025Article
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Prevalence of Neoplasms in Patients with Acromegaly-A Single-Center Polish Study.Journal of clinical medicine · 2024Article
- Lipoprotein alterations in endocrine disorders - a review of the recent developments in the field.Frontiers in endocrinology · 2024Review
- Osteosarcopenia in acromegaly: reduced muscle quality and increased vertebral fat deposition.Journal of endocrinological investigation · 2023Article
- The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status.Journal of clinical medicine · 2023Article
- Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.Journal of the Endocrine Society · 2023Article
- Article
- Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study.Biomedicines · 2023Article
- Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.Frontiers in endocrinology · 2023Article
- Acromegaly among a Moroccan population.The Pan African medical journal · 2023Article
- Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.Frontiers in endocrinology · 2023Review
- Corneal Tonometric and Morphological Changes in Patients with Acromegaly.Journal of clinical medicine · 2022Article
- [Cardiovascular complications associated with acromegaly. A state-of-the-art].Archivos de cardiologia de Mexico · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In acromegaly, chronic exposure to impaired GH and IGF-I levels leads to the development of typical acromegaly symptoms, and multiple systemic complications as cardiovascular, metabolic, respiratory, endocrine, and bone disorders. Acromegaly comorbidities contribute to decreased life quality and premature mortality. The aim of our study was to assess the frequency of acromegaly complications and to evaluate diagnostic methods performed toward recognition of them. Materials and Methods: It was a retrospective study and we analyzed data of 179 patients hospitalized in the Department of Endocrinology, Diabetes and Isotope Therapy in Wroclaw Medical University (Poland) in 1976 to 2018 to create a database for statistical analysis. Results: The study group comprised of 119 women (66%) and 60 men (34%). The median age of acromegaly diagnosis was 50.5 years old for women (age range 20-78) and 46 for men (range 24-76). Metabolic disorders (hyperlipidemia, diabetes, and prediabetes) were the most frequently diagnosed complications in our study, followed by cardiovascular diseases and endocrine disorders (goiter, pituitary insufficiency, osteoporosis). BP measurement, ECG, lipid profile, fasting glucose or OGTT were performed the most often, while colonoscopy and echocardiogram were the least frequent. Conclusions: In our population we observed female predominance. We revealed a decrease in the number of patients with active acromegaly and an increase in the number of well-controlled patients. More than 50% of patients demonstrated a coexistence of cardiac, metabolic and endocrine disturbances and only 5% of patients did not suffer from any disease from those main groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.